Neoadjuvant Therapy for Resettable Pancreatic Adenocarcinoma: It's Time to Define High-Risk Factors

J Surg Oncol. 2025 Jan 9. doi: 10.1002/jso.28082. Online ahead of print.

Authors

Xiang Zhou¹, Shunqi Xie¹

Affiliation

¹ Department of Hepatobiliary Surgery, People's Hospital of Wenjiang District, Chengdu, China.

PMID: 39789867
DOI: 10.1002/jso.28082

No abstract available

Publication types

Letter